Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) announced today that Kenneth Keiler, Ph.D., Professor of Molecular Biosciences at the University of Texas at Austin, has been awarded a research grant for his innovative project titled "Inhibitors of the Gram-negative Cell Envelope Stress Response as Anti-Infectives and Antibiotics.
" This funding will support Dr. Keiler's original approach to addressing the critical issue of antibiotic-resistant Gram-negative bacterial infections. Despite the availability of numerous approved medicines for Gram-negative infections, the rapid rise in antibiotic resistance far outpaces the development of new therapeutic options.
Such resistance is particularly severe in hospital environments, where multi-drug-resistant strains pose significant treatment challenges. Dr. Keiler's research focuses on developing inhibitors that target the stress response systems of Gram-negative bacteria.
His research could lead to new treatments for life-threatening infections caused by Gram-negative pathogens, offering a promising solution to an urgent medical need. We are delighted to support Dr. Keiler's inventive work.
His approach to target the stress response systems of Gram-negative bacteria represents a significant leap forward in our fight against antibiotic resistance. This research has the potential to develop new treatments that are not subject to the current resistance mechanisms, which is crucial for improving patient outcomes." Maaike Everts, Ph.
D., Executive Director of TRxA Dr. Keiler expressed his gratitude for the grant, stating, "I am honored to receive this support from TRxA and am eager to advance our research.
Addressing the challenge of antibiotic resistance in Gram-negative bacteria is imperative, and we believe that by targeting their stress response systems, we can develop effective new treatments that will significantly impact patient care." TRxA's support for Dr. Keiler's research highlights C-Path's dedication to advancing innovative solutions that accelerate the development of therapies for people with unmet medical needs.
Critical Path Institute (C-Path).
